Monkasta (Montelukast)

Monkasta belongs to the leukotriene receptor antagonist class and is indicated for conditions driven by leukotriene‑mediated airway inflammation.

• Asthma: improves long‑term control and reduces the frequency of asthma attacks.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens.
• Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By preventing leukotriene binding, it reduces bronchoconstriction, mucus secretion, and inflammatory cell recruitment, thereby improving airway patency and decreasing the frequency of asthma and allergy symptoms.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often reported during early treatment.
• Abdominal pain: discomfort or cramps in the stomach region.
• Cough: transient irritation of the airway.
• Nasopharyngitis: mild upper respiratory tract infection symptoms.
• Diarrhoea: loose stools occurring occasionally.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention.
• Neuropsychiatric events: agitation, depression, or suicidal thoughts.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Churg‑Strauss syndrome: rare vasculitis with asthma worsening.
• Severe bronchospasm: sudden worsening of breathing despite therapy.

Before initiating Monkasta, consider patient‑specific factors and safety measures.

• Hypersensitivity: avoid use in individuals with known allergy to montelukast or any tablet excipients.
• Psychiatric history: monitor for mood changes, especially in children and adolescents.
• Liver disease: use cautiously and assess hepatic function periodically.
• Pregnancy and lactation: discuss potential risks with the prescriber; data are limited.
• Pediatric use: dosing and safety should be determined by a qualified healthcare professional.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce therapeutic effect.
• Phenobarbital: decreases plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase montelukast levels, requiring observation for side effects.
• Fluconazole: modestly raises exposure; monitor for adverse reactions.
• Warfarin: occasional reports of altered INR; check coagulation parameters as needed.